China’s Hutchmed inks $1.3 B deal with GSK for KRAS-EGFR-antibody conjugate cancer therapy
China’s Hutchmed inks $1.3 B deal with GSK for KRAS-EGFR-antibody conjugate cancer therapy September 4, 2026 | Friday…
Browsing Tag